MedPath

FDA Rejects Atara Biotherapeutics' Blood Cancer Treatment, Shares Plunge

Atara Biotherapeutics faced a significant setback as the FDA rejected its application for a blood cancer treatment, leading to a sharp decline in its stock value. The company plans to address the FDA's concerns, primarily related to a third-party manufacturing facility, and resubmit the application, expecting approval within six months. To support its efforts, Atara has secured potential funding and is considering strategic options including a merger or acquisition.

FDA Rejects Atara Biotherapeutics' Blood Cancer Treatment

Atara Biotherapeutics experienced a dramatic drop in its stock value following the FDA's rejection of its application for a new blood cancer treatment. The company's shares fell by 46.5% to $7.04, marking a significant downturn over the past six months and year.

The FDA's Complete Response Letter

The FDA issued a complete response letter to Atara, indicating that the application for its drug, Ebvallo, would not be approved in its current form. Ebvallo is designed to treat a rare form of blood cancer that occurs in patients who have undergone transplants. Importantly, the FDA's concerns were not related to the drug's safety or efficacy but stemmed from observations made during an inspection of a third-party manufacturing facility.

Atara's Next Steps

Atara Biotherapeutics has announced its intention to address the FDA's concerns and resubmit the application. The company is optimistic about receiving approval within six months of resubmission. To support these efforts, Atara has entered into a non-binding term sheet with Redmile Group, a San Francisco-based private equity manager, for funding of up to $15 million. Additionally, the company is exploring strategic options, including a potential merger or acquisition, to strengthen its position and continue its mission of bringing innovative treatments to patients.

Impact on Atara and the Pharmaceutical Industry

This development underscores the challenges faced by biotech companies in navigating the regulatory landscape and the importance of manufacturing compliance in the drug approval process. Atara's experience highlights the critical role of third-party facilities in the production of pharmaceuticals and the potential impact of regulatory decisions on company valuations and investor confidence.
As Atara works towards addressing the FDA's concerns and resubmitting its application, the pharmaceutical industry will be watching closely. The outcome of this process could have significant implications for the treatment of rare blood cancers and the broader biotech sector.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Rejects Atara's Cell Therapy for Rare Transplant Complication

The FDA has declined approval for Atara Biotherapeutics' cell therapy aimed at treating a rare complication following transplants, leading to a significant drop in the company's stock value. This decision underscores the challenges in developing treatments for complex post-transplant conditions.

FDA Places Clinical Hold on Atara Biotherapeutics' Cell Therapy Programs Due to Manufacturing Concerns

The FDA has placed a clinical hold on Atara Biotherapeutics' EBVALLO (tabelecleucel) program and ATA3219, pausing new patient enrollment.

Teva's Long-Acting Schizophrenia Drug Rejected by FDA

The FDA has declined to approve Teva's long-acting formulation of schizophrenia drug risperidone, dealing a blow to the company's turnaround efforts. Despite positive phase 3 trial results, the reasons for the rejection remain undisclosed, with Teva and partner MedinCell planning to address the FDA's concerns.

Mersana Therapeutics Stock Drops Following Phase 1 Trial Data Release

Mersana Therapeutics Inc. saw its stock price drop by 36.6% after releasing initial data from the Phase 1 trial of emiltatug ledadotin, despite showing promising results in treating B7-H4 high tumors and triple-negative breast cancer.

FDA Rejects Applied Therapeutics' Govorestat for Galactosemia, Citing Clinical Application Deficiencies

The FDA has rejected Applied Therapeutics' marketing application for govorestat for the treatment of galactosaemia due to deficiencies in the clinical application.

FDA Rejects Accelerated Approval for Kazia's Paxalisib in Glioblastoma

The FDA has declined to grant accelerated approval for Kazia Therapeutics' paxalisib for treating glioblastoma, leading to a stock decrease.

Repare Therapeutics' Gynecological Cancer Trial Shows Mixed Results, Beigene Inks $1.5B Deal for MAT2A Inhibitor

Repare Therapeutics' phase I trial of lunresertib and camonsertib in gynecological cancers with specific biomarkers showed mixed results, impacting stock prices.

FDA Rejects Astellas' Izervay Update; Cytokinetics and Bayer Announce Aficamten Licensing Deal

The FDA rejected Astellas' request to update Izervay's prescribing information for bi-monthly injections due to a statistical matter, maintaining Apellis' dosing advantage.

FDA Issues Complete Response Letter for Camurus' Acromegaly Drug CAM2029

The FDA issued a Complete Response Letter (CRL) for Camurus' CAM2029, an extended-release octreotide injection, intended for treating acromegaly, citing manufacturing deficiencies.

RAPT Therapeutics Halts Zelnecirnon Trials in Atopic Dermatitis and Asthma Following FDA Clinical Hold

RAPT Therapeutics has decided to close and unblind its Phase 2b trial of zelnecirnon in atopic dermatitis and its Phase 2a trial in asthma after an FDA clinical hold.

Reference News

[1]
Atara Shares Sink After FDA Stalls Cancer Treatment
morningstar.com · Jan 16, 2025

Atara Biotherapeutics' shares dropped 46.5% after FDA rejected its blood cancer treatment application. The FDA's concern...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy